Member Info for ogm4

The next pharma patent cliff: how 2026-2032 will reshape revenue

By Jules Adam

February 16, 2026

Updated March 23, 2026

https://www.labiotech.eu/best-biotech/pharma-patent-cliff/

Until 2030 the pharma sector will experience a so-called 'patent cliff' meaning nearly 200 specific drugs will loose their patents affecting billions of global revenue.

Watch this space...

UCB inks $2B Candid buyout to join Gilead in autoimmune field

By Nick Paul Taylor

May 4, 2026 7:46am

https://www.fiercebiotech.com/biotech/ucb-inks-2b-candid-buyout-join-gilead-autoimmune-field

Read the RNS 27 March:

"P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026."

Publication submission must be well underway as they have been working at least 2 months on it by now, maybe even longer. Plus the R&D team already knows the P140 product in detail with additional studies done.

P140 is still the main focus (has not changed one iota...)

https://youtu.be/kyeKEyHfJDE?is=ouTgK3GjYWc-N39u

24-Apr-26 11:43:51 4.60 418,817 Unknown* 19.27k O

24-Apr-26 11:43:51 4.60 418,600 Unknown* 19.26k O

Massive patent cliff coming for autoimmune diseases between now and 2030, with many major blockbusters losing patent exclusivity. Major pharma companies on the lookout for new innovative solutions.

DYOR

Patent cliff coming...

https://clival.com/blog/15-biologics-are-going-off-patent-2025-to-2029

Https://www.fiercebiotech.com/biotech/lilly-reneges-remainder-rigel-deal-another-blow-ripk1-inhibitors

Lilly, Genentech, Sanofi and GSK could be out on the hunt again as no doubt they will be looking for other new autoimmune disease treatments / solutions...

Who knows...

Https://trial.medpath.com/news/14b6a9e202d58dc8/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems

Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and *** selectively invest in earlier-stage pipeline opportunities. ***

Are there more surprises 'coming from the left' soon then?

I'd prefer the company focussing on P140 and Kapiglucagon first tbh as these have huge potential in the current global markets.

Another 500,000 has appeared

UCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager deal

https://european-biotechnology.com/latest-news/ucb-licenses-antengenes-atg-201-in-1-1b-autoimmune-masked-t-cell-engager-deal/

J&J secures $500M Royalty backing for autoimmune antibody program

By Darren Incorvaia

Mar 30, 2026 10:07am

https://www.fiercebiotech.com/biotech/jj-secures-royalty-backing-500m-autoimmune-antibody-program

Bit of uptrend showing today so far

ImmuPharma advances P140 partnering strategy following £6.5m raise

Abm April 9, 2026

https://www.share-talk.com/immupharma-advances-p140-partnering-strategy-following-6-5m-raise/

ImmuPharma raises up to £7.5m to accelerate diabetes drug development

Proactive

17 March 2026 2 min read

https://uk.finance.yahoo.com/news/immupharma-raises-7-5m-accelerate-071200803.html

IMM potentially never has been in a better position before with £6 Million GBP additional cash and two flagships under development.

In all fairness i think we've reached the bottom sp now. From now on frequent news updates to be expected with at least 2.5 more years cash in the bank until late 2028!

£6 Million GBP additional funds obtained for commercial Kapiglucan development started this week.

Atb